market Inner Banner
  • BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ticker-arrow
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Sun Pharma gets nod for Semaglutide injection in South Africa
Back
(09:47, 15 Jul 2026)
The drug will be used for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths'2 mg/1.5 mL and 4 mg/3 mL'allowing flexible, once-weekly dosing.

'South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, chief operating officer, Sun Pharma.

The company said that South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and the healthcare system. Improving access to effective therapies is therefore an important component of addressing this national health challenge.

Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to the global market. It is the largest pharmaceutical company in India.

The company had reported a 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026.

The scrip rose 0.46% to currently trade at Rs 1,949 on the BSE.

Powered by Capital Market - Live News

Top
Scores
Scores 2.O
Online Dispute Redressal (ODR)
Investor Charter
Invester Complaint
Advisory for Investors
Liquidity Enhancement Scheme
KYC documents in vernacular languages
KYC documents in vernacular languages of commodities
.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY) 		Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355
51, Mini Market T/F Mandir Wali Gali, Yusaf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 201002 0120-4150393 ghaziabad@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road, Delhi 110001- 0120-4823200 compliance@dbonline.in
Daga Business (International) Stock Brokers (IFSC) Private Limited INZ000202436 Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, Gift SEZ, Gandhinagar, Gujarat 382355 - 0120-4823200 compliance@dbonline.in

Disclosure regarding proprietary trading:

As required under Circular No. SEBI/MRD/SE/Cir-42/2003 dated 19.11.2003 issued by the Securities and Exchange Board of India; We hereby disclose that in addition to client based business, We are also doing proprietary trading.

Investor Grievances Email ID: investorgrievance@dbonline.in


Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)
Attention Investors ::
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"